BRIEF — Eton Pharmaceuticals Under Agreement, Co Pays Aquestive Upfront License Fee Of $10 Million — SEC Filing

Oct 14 (Reuters) — Eton Pharmaceuticals Inc: Eton Pharmaceuticals - Under Agreement, Co Pays Aquestive Upfront License Fee Of $10 Million - Sec Filing Eton Pharmaceuticals - To Pay Aquestive Up To $47.50 Million In Milestone Payments - Sec Filing Eton Pharmaceuticals - To Pay Aquestive Royalties At Mid-teens Percentage Rate On Libervant Sales - Sec Filing Eton Pharmaceuticals - Entered Into Supply Agreement With Aquestive; Agreement For Libervant Has Initial Term Of 20 Years - Sec Filing Source text:... Further company coverage: ETON.O (Reuters.Briefs@thomsonreuters.com;)